Opendata, web and dolomites

VSV-EBOVAC SIGNED

Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VSV-EBOVAC project word cloud

Explore the words cloud of the VSV-EBOVAC project. It provides you a very rough idea of what is the project "VSV-EBOVAC" about.

mid    primates    leaders    antibody    generation    candidates    harvested    accelerate    stomatitis    zaire    innate    ebola    african    populations    months    ebovac    initiated    africa    volunteers    vsv    world    inducing    vectored    newlink    immune    humans    gabon    primary    technologies    emphasis    vaccines    supporting    switzerland    vesicular    2014    aditec    parallel    man    organization    200    doses    characterization    powerful    dose    cutting    public    perform    single    fp7    virus    determinants    infections    edge    adaptive    imi2    november    asset    elicited    sites    immunization    acquire    genetics    safety    collaborative    manufacturer    critical    immunology    protective    signatures    samples    kenya    efficacy    scientists    lasting    persistent    extend    health    trials    vaccine    vaccination    metabolomics    capacity    canada    candidate    12    immunisation    manufactured    zebov    human    constructed    trancriptomics    100    first    clinical   

Project "VSV-EBOVAC" data sheet

The following table provides information about the project.

Coordinator
SCLAVO VACCINES ASSOCIATION 

Organization address
address: PIAZZA LA LIZZA 7
city: SIENA
postcode: 53100
website: www.sclavo.org/home

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.vsv-ebovac.eu
 Total cost 4˙786˙010 €
 EC max contribution 3˙887˙260 € (81%)
 Programme 1. H2020-EU.3.1.7.13. (Other)
 Code Call H2020-JTI-IMI2-2014-02-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2015
 Duration (year-month-day) from 2015-03-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCLAVO VACCINES ASSOCIATION IT (SIENA) coordinator 841˙250.00
2    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 700˙000.00
3    EMORY UNIVERSITY NON PROFIT CORP US (Atlanta) participant 600˙888.00
4    UNIVERSITA DEGLI STUDI DI SIENA IT (SIENA) participant 562˙500.00
5    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 522˙552.00
6    MICROBIOTEC SRL IT (MONTERIGGIONI) participant 212˙500.00
7    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 131˙820.00
8    Department of Health UK (Leeds) participant 125˙000.00
9    Centre de Recherches Medicales de Lambaréné GA (Lambaréné) participant 118˙875.00
10    BIOPROTECTION SYSTEMS CORPORATION US (AMES) participant 62˙500.00
11    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 9˙375.00
12    EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT CH (BERN) participant 0.00
13    UNIVERSITE DE GENEVE CH (GENEVE) participant 0.00

Map

 Project objective

The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promising new Ebola vaccine candidate, the vesicular stomatitis virus (VSV)‐ vectored Zaire Ebola vaccine (VSV-ZEBOV). In non-human primates, a single dose of VSV-ZEBOV elicited a strong (100%) and long-lasting protective efficacy against Ebola Zaire infections. Developed by Public Health Canada and manufactured by NewLink Genetics, VSV-ZEBOV was thus selected by the World Health Organization (WHO) as one of the 2 most promising vaccine candidates. To accelerate its clinical development, the WHO has organized a consortium and supported the organization of parallel first-in-man Phase I/II clinical trials, both in Europe and Africa. The primary objectives of these trials, initiated mid-November 2014, are to study the safety and antibody-inducing capacity of various doses of VSV-ZEBOV in European and African populations.

We propose to build upon this asset to acquire new and critical knowledge of the innate and adaptive immune responses elicited in humans by VSV-ZEBOV vaccination, with specific emphasis on trancriptomics and metabolomics signatures. To this aim, we have constructed a consortium including representatives from the vaccine manufacturer, scientists of the 3 main clinical sites (Switzerland, Gabon, Kenya) and world-leaders in immunology and partners of ADITEC, a large FP7- supported collaborative research programme aiming to accelerate the development of novel, powerful immunisation technologies for next-generation vaccines. We propose an ambitious program using cutting-edge technologies to perform an in depth characterization of the clinical samples harvested before/after VSV-ZEBOV immunization of 200 volunteers in Switzerland, Gabon and Kenya, and to extend the recently initiated clinical studies up to 12 months to identify the signatures and determinants of persistent immune responses.

 Deliverables

List of deliverables.
Predictive correlates of protective immunity and safety determined. Documents, reports 2019-10-01 09:22:26
Establishment of the External Advisory Board Documents, reports 2019-06-19 17:57:00
Distribution of early samples (day 0-14) to partners involved in immunogenicity studies Documents, reports 2019-06-19 17:57:00
Distribution of intermediate samples (day 28) to partners involved in immunogenicity studies Documents, reports 2019-06-19 17:57:00
Web site development and maintenance Websites, patent fillings, videos etc. 2019-06-19 17:57:00
Distribution of late samples (> day 28) to partners involved in immunogenicity studies Documents, reports 2019-06-19 17:57:00

Take a look to the deliverables list in detail:  detailed list of VSV-EBOVAC deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Donata Medaglini, Claire-Anne Siegrist
Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine
published pages: 88-94, ISSN: 1879-6257, DOI: 10.1016/j.coviro.2017.03.008
Current Opinion in Virology 23 2019-06-19
2018 Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, José F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara Lemaître, Stéphane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist, Sanjeev KRISHNA, Marylyn M. ADDO, Stephan BECKER, Verena KRÄHLING, Patricia NJUGUNA, Marie-Paule KIENY, Rafi AHMED, Jenna ANDERSON, Floriane AUDERSET, Luisa BORGIANNI, Annalisa CIABATTINI, Marielle C. HAKS, Ali HARANDI, Donald Gray HEPPNER, Alice GERLINI, Donata MEDAGLINI, Tom H.M. OTTENHOFF, David PEJOSKI, Mark PAGE, Gianni POZZI, Francesco SANTORO, Sheri DUBEY, José F. FERNANDES, Helder NAKAYA, Fiona OROURKE, Gianni POZZI, Sylvia ROTHENBERGER
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
published pages: 738-748, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(18)30165-8
The Lancet Infectious Diseases 18/7 2019-06-19
2018 Angela Huttner, Claire-Anne Siegrist
Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
published pages: 1105-1110, ISSN: 1476-0584, DOI: 10.1080/14760584.2018.1546582
Expert Review of Vaccines 17/12 2019-06-19
2017 Angela Huttner, Christophe Combescure, Stéphane Grillet, Mariëlle C. Haks, Edwin Quinten, Christine Modoux, Selidji Todagbe Agnandji, Jessica Brosnahan, Julie-Anne Dayer, Ali M. Harandi, Laurent Kaiser, Donata Medaglini, Tom Monath, Pascale Roux-Lombard, Peter G. Kremsner, Tom H. M. Ottenhoff, Claire-Anne Siegrist
A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa
published pages: eaaj1701, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aaj1701
Science Translational Medicine 9/385 2019-06-19
2018 Donata Medaglini, Francesco Santoro, Claire-Anne Siegrist
Correlates of vaccine-induced protective immunity against Ebola virus disease
published pages: 65-72, ISSN: 1044-5323, DOI: 10.1016/j.smim.2018.07.003
Seminars in Immunology 39 2019-06-19

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VSV-EBOVAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VSV-EBOVAC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.13.)

EBOVAC1 (2014)

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854

Read More  

VSV-EBOVAC (2015)

Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842

Read More  

ADAPT-SMART (2015)

Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes - Sofia ref.: 115890

Read More